Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 11/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSH | P09668 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL8202526 | 0.97 | MMP2 (0.48) | MMP2MMP9MMP8CTSSGAA | |
| Leucine SCHEMBL1406254 | 0.97 | MMP2 (0.50) | MMP2MMP9MMP8CTSSGAA | |
| Leucine SCHEMBL3812226 | 0.95 | MMP2 (0.48) | MMP2MMP9MMP8CTSSGAA | |
| Leucine SCHEMBL2297615 | 0.94 | MMP2 (0.49) | MMP2MMP9MMP8CTSSGAA | |
| SCHEMBL233988 | 0.88 | MMP2 (0.48) | MMP2MMP9MMP8CTSSGAA | |
| SCHEMBL2302161 | 0.87 | CTSS (0.45) | MMP2MMP9MMP8CTSSGAA | |
| SCHEMBL756847 | 0.87 | KDM4E (0.55) | MMP2MMP9MMP8CTSSGAA | |
| SCHEMBL2780950 | 0.87 | KDM4E (0.55) | MMP2MMP9MMP8CTSSGAA | |
| Leucine SCHEMBL1406330 | 0.84 | CTSS (0.62) | CTSSGAACTSBCTSKCTSL | |
| Leucine SCHEMBL4971766 | 0.83 | CTSS (0.48) | CTSSGAACTSBCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7119080-B2 | For use as inhibitors of proteasome; for reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1312609-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6747150-B2 | FOR REDUCING RATE OF DEGRADATION OF PROTEINS IN AN ANIMAL; INHIBITING HIV REPLICATION | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030199561-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-6548668-B2 | Stabilizer for proteins | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020173488-A1 | Boronic Ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MMP2 1697/4885MMP9 3861/4885MMP8 1304/4885 |
| US-20030199561-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MMP2 1366/4885MMP9 3742/4885MMP8 1012/4885 |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MMP2 1697/4885MMP9 3861/4885MMP8 1304/4885 |
| US-20020173488-A1 | Boronic Ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | MMP2 1366/4885MMP9 3742/4885MMP8 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.